CN107708674A - 联合hiv疗法 - Google Patents

联合hiv疗法 Download PDF

Info

Publication number
CN107708674A
CN107708674A CN201680029646.XA CN201680029646A CN107708674A CN 107708674 A CN107708674 A CN 107708674A CN 201680029646 A CN201680029646 A CN 201680029646A CN 107708674 A CN107708674 A CN 107708674A
Authority
CN
China
Prior art keywords
particle
bryostatin
virus
disease
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680029646.XA
Other languages
English (en)
Chinese (zh)
Inventor
T.P.卡斯托尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aphios Corp
Original Assignee
Aphios Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aphios Corp filed Critical Aphios Corp
Publication of CN107708674A publication Critical patent/CN107708674A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680029646.XA 2015-05-22 2016-05-23 联合hiv疗法 Pending CN107708674A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165444P 2015-05-22 2015-05-22
US62/165444 2015-05-22
PCT/US2016/033766 WO2016191363A1 (en) 2015-05-22 2016-05-23 Combination hiv therapeutic

Publications (1)

Publication Number Publication Date
CN107708674A true CN107708674A (zh) 2018-02-16

Family

ID=57394156

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029646.XA Pending CN107708674A (zh) 2015-05-22 2016-05-23 联合hiv疗法

Country Status (5)

Country Link
US (1) US10493030B2 (https=)
EP (1) EP3297608B1 (https=)
JP (2) JP6816030B2 (https=)
CN (1) CN107708674A (https=)
WO (1) WO2016191363A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3560492B1 (en) * 2016-12-26 2023-11-29 FUJIFILM Corporation Lipid particle composition and pharmaceutical composition
US11234932B2 (en) * 2017-11-21 2022-02-01 Aphios Corporation Combination HIV therapeutic
US20210163935A1 (en) * 2019-09-05 2021-06-03 Trevor P. Castor Targeted Critical Fluid Nanoparticles Platform for Delivery of Nucleic Acids for Treatment of HIV-1 and Other Diseases
WO2021183131A1 (en) * 2020-03-12 2021-09-16 Aphios Corporation Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100166806A1 (en) * 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
US8237074B2 (en) * 2008-03-05 2012-08-07 Moeller Gebäudeautomation GmbH Switching device
US20130156822A1 (en) * 2011-12-19 2013-06-20 Aphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013165592A1 (en) * 2012-05-03 2013-11-07 Volpe Joseph M Treatment of latent hiv infection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007345319B2 (en) * 2006-07-13 2012-09-06 Institute For Advanced Study Viral inhibitory nucleotide sequences and vaccines
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
US8637074B2 (en) * 2009-03-31 2014-01-28 Aphios Corporation Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product
ES2618380T3 (es) * 2010-09-24 2017-06-21 International Aids Vaccine Initiative Novedosos anticuerpos con amplio poder neutralizante de VIH-1
KR102460800B1 (ko) * 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자
US11234932B2 (en) * 2017-11-21 2022-02-01 Aphios Corporation Combination HIV therapeutic

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8237074B2 (en) * 2008-03-05 2012-08-07 Moeller Gebäudeautomation GmbH Switching device
US20100166806A1 (en) * 2008-12-29 2010-07-01 Aphios Corporation Combination therapy comprising the use of protein kinase C modulators and Histone Deacetylase inhibitors for treating HIV-1 latency
US20130156822A1 (en) * 2011-12-19 2013-06-20 Aphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013165592A1 (en) * 2012-05-03 2013-11-07 Volpe Joseph M Treatment of latent hiv infection

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL C. BUEHLER: "Bioengineered Vaults: Self-Assembling", 《ACS NANO》 *
LYNN M. SCHLICHTER: "Successful Treatment of Murine Melanoma with Bryostatin 1", 《CANCER RESEARCH》 *
MICHAEL KOVOCHICH等: "Activation of Latent HIV Using Drug-Loaded", 《PLOS ONE》 *
杨解人等: "《临床药学与药物治疗学》", 31 March 2009, 军事医学科学出版社 *

Also Published As

Publication number Publication date
WO2016191363A8 (en) 2017-10-12
JP6816030B2 (ja) 2021-01-20
HK1253011A1 (en) 2019-06-06
JP2018515567A (ja) 2018-06-14
EP3297608A4 (en) 2019-01-16
JP7111795B2 (ja) 2022-08-02
EP3297608A1 (en) 2018-03-28
WO2016191363A1 (en) 2016-12-01
US20180133155A1 (en) 2018-05-17
JP2021054853A (ja) 2021-04-08
EP3297608B1 (en) 2022-07-13
US10493030B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
JP7111795B2 (ja) 組合せｈｉｖ治療薬
KR970007187B1 (ko) 개선된 암포테리신 b 리포좀 제조법
JP6751424B2 (ja) ダイズホスファチジルセリンで作られたコクリエート
Ripoli et al. Phytoliposome-based silibinin delivery system as a promising strategy to prevent hepatitis C virus infection
Zhang et al. Advances in nanomaterial-targeted treatment of acute lung injury after burns
Burlec et al. Exploring the therapeutic potential of natural compounds in psoriasis and their inclusion in nanotechnological systems
Ataide et al. Co-encapsulation of drugs for topical application—A review
Zhang et al. pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model
Meng et al. Pharmacologic therapies of ARDS: from natural herb to nanomedicine
CN109224084A (zh) Tpgs修饰的多西他赛脂质体纳米给药系统及及其制备方法、应用
Shanmugam et al. Aerosol delivery of paclitaxel-containing self-assembled nanocochleates for treating pulmonary metastasis: An approach supporting pulmonary mechanics
Ruckmani et al. Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes
US11234932B2 (en) Combination HIV therapeutic
WO2022036278A1 (en) Immunomodulation formulations and related methods
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
CN114652683B (zh) 一种Mdivi-1纳米长循环脂质体及其制备方法和应用
Jaimalai et al. Drug delivery system targeting CD4+ T Cells for HIV-1 latency reactivation towards the viral eradication
CN106177959A (zh) 抗癌组合物及其制剂和应用
Sankar et al. Comparative studies of lamivudine-zidovudine nanoparticles for the selective uptake by macrophages
Qadir et al. Pinpoint and Stewardship of Psoriasis by Using Phytoconstituent-based Novel Formulation
HK1253011B (en) Combination hiv therapeutic
Thamrook et al. Applications of lipid Core Nanocapsules: novel drug delivery system
JPWO2011142484A1 (ja) ポリアルキレンイミンを含むウイルス感染症治療薬
WO2016167730A1 (en) Nanomicelles for the treatment of cancer
CN114450001A (zh) 18β-甘草次酸的纳米乳液

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180216

RJ01 Rejection of invention patent application after publication